Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

PURPOSE: To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Children's Oncology Group (COG) clinical trials between 1990 and 2005. PATIENTS AND METHODS: In total, 21,626 persons age 0 to 22 years were enrolled onto COG ALL clinical trials from 1990 to 2005, representing 55.8% of ALL cases estimated to occur among US persons younger than age 20 years during this period. This period was divided into three eras (1990-1994, 1995-1999, and 2000-2005) that included similar patient numbers to examine changes in 5- and 10-year survival over time and the relationship of those changes…

• BS
  Bristol-Myers Squibb
• S
  Sanofi
• TP
  Teva Pharmaceutical Industries
• AS
  American Society of Clinical Oncology
• EP
  Enzon Pharmaceuticals
• CO
  Children’s Oncology Group

  Awards: U10 CA98413, U10 CA98543
• EP
  EUSA Pharma
• NI
  National Institutes of Health

  Awards: U10 CA98413, U10 CA98543, CA98413, CA114766, U24 CA114766, CA98543
• NC
  National Cancer Institute

  Awards: CA114766, CA98543, U10 CA98543, U10 CA98413, CA98413, U24 CA114766